Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer

Setidegrasib was associated with antitumor activity and a low incidence of treatment discontinuation due to adverse events in patients with previously treated advanced <i>KRAS</i> p.G12D-mutated NSCLC or pancreatic ductal adenocarcinoma. (Funded by Astellas Pharma; ClinicalTrials.gov number, NCT05382559.).